

# Index

- abdominal massage, 220  
 acetaminophen, for PLP, 162  
 acetylcholine, 81  
 achalasia, 58  
 active exercise, for spasticity, 122–3  
 active rehabilitation, 5  
 activities of daily living (ADL), 4  
   instrumental, 76–9  
 Activity Card Sort, 42  
 activity co-ordinators, 5  
 acupuncture, 146  
   clinical trials on, 64  
   for hypersalivation, 62–3  
   for xerostomia, 62–3  
 AD. *See* autonomic dysreflexia  
 adaptation exercises, 93–4  
   in vestibular rehabilitation, 94–6  
 adaptive interventions, 7  
 adjustment disorders, 22–3  
   factors affecting, 23  
   pharmacological management of, 22–3  
   symptoms of, 22  
   treatment, 22–3  
 ADL. *See* activities of daily living  
 aging, dysphagia and, 52–3  
 AIE. *See* anoxic-ischemic encephalopathy  
 alpha blockers, 209  
 ALS, 57  
   incidence of, 62–3  
 alternating attention, 13  
 Alzheimer's dementia, 107–8  
 amantadine, 45  
   for DOC, 36–8  
   evidence, 36–8  
   indication for, 36–8  
   for Parkinson's disease, 140  
   rationale for, 36–8  
   side effects of, 36–8  
 ambulatory blood pressure  
   measurements, in AD, 197  
 anomic aphasia, 14  
 anoxic-ischemic encephalopathy (AIE), 32  
 antegrade irrigation surgery, 220–1  
 anticholinergic medications  
   contraindications for, 70  
   for hypersalivation, 69  
   for Parkinson's disease, 140  
 anticonvulsants, for PLP, 163  
 antidepressants, 23  
   effects of, 24–5  
   for PLP, 162–3  
   side effects of, 25  
 antihistamines, 62–3  
 antipsychotics, 26, 28, 62–3  
 anxiety disorders, 25–6  
   meta-analysis of studies on, 25  
   MS and, 25  
   Parkinson's disease and, 25  
   pharmacologic management of, 26  
   SSRIs for, 26  
   stroke and, 25  
   walking and, 108  
 anxiolytics, 23  
 AOS. *See* apraxia of speech  
 aphasia, 31  
   anomic, 14  
   chronic, 43, 46–7  
   Cochrane review on, 42  
   conduction, 14  
   global, 14  
   pharmacological interventions for, 44–5  
   rTMS for, 43–4  
   tDCS for, 44  
 apomorphine, 139  
   for Parkinson's disease, 142  
 applied relaxation, 25–6  
 apraxia of speech (AOS), 41, 44  
 APT. *See* Attention Processing Training  
 ARAS. *See* ascending reticular activating system  
 arousal, 30  
 artificial urinary sphincter (AUS), 212–13  
 ascending reticular activating system (ARAS), 32  
 aspiration, 57  
 assessments, in neurorehabilitation, 1  
 atropine, 63  
   action of, 68  
   for hypersalivation, 68–9  
 attention  
   alternating, 13  
   divided, 13  
   evidence-based cognitive rehabilitation for, 13  
   focused, 13  
   impairment of, 13  
   selective, 13  
   sustained, 13  
 Attention Processing Training (APT), 13  
 augmentation cystoplasty, for LUT, 211–12  
 augmented feedback, for upper limb impairment, 79  
 augmenting interventions, 6  
 AUS. *See* artificial urinary sphincter  
 autonomic dysreflexia (AD), 196–7  
   ambulatory blood pressure measurements, 197  
   boosting, 198  
   causes of, 197  
   procedures causing, 197  
   signs of, 197  
   treatment of, 197  
 baclofen, 126  
   intrathecal, 38, 81, 129–30  
   for spasticity, 125  
 balance, 105–7  
   walking and, 113  
 barbecue rotation, 101  
 baroreflex, 186  
 Barthel index, 4  
 basal ganglia, 107  
 BDNF. *See* Brain Derived Neurotrophic Factor  
 Beck Anxiety Inventory, 25  
 behavioural disorders, 22  
 behavioural modifications, for hypersalivation, 66  
 behavioural therapy, toileting and, 207  
 Benign Paroxysmal Positional Vertigo (BPPV)  
   defining, 90  
   evidence-base for, 100–1  
   horizontal canal, 101  
   posterior canal, 100

- posterior semicircular canal, 90  
 repositioning manoeuvres for, 91, 100–1
- benzodiazepines, 23, 26, 28  
 for spasticity, 127
- beta-blockers, 28, 62–3
- bifemelane, 45
- biofeedback, 6  
 for dysphagia, 56–7  
 for neurogenic bowel dysfunction, 220  
 for PLP, 162  
 for upper limb impairment, 79
- biomarkers, 47
- biomedical engineers, 5
- bipedal standing, 105
- bipolar disorder, MS and, 26
- bladder outlet dysfunction, 212
- blood pressure regulation, 188
- Bobath approach, for upper limb impairment, 79
- Bobath's neurodevelopmental approach, 6–7
- body scan, 18
- body schema concept, 159
- botulinum toxin (BoNT), 58, 63, 81  
 for dysphagia, 58  
 for hypersalivation, 67–8  
 for LUT, 210–11  
 in neuropathic pain, 154–5  
 for Parkinson's disease, 140  
 for spasticity, 128–9
- BPPV. *See* Benign Paroxysmal Positional Vertigo
- brachytherapy, 58
- Braden Scale, 180
- Brain Derived Neurotrophic Factor (BDNF), 75–6
- brain mapping, 43
- brain-machine interfaces, for upper limb impairment, 81–2
- Brief Pain Inventory, 160
- Brindley stimulator, 213
- Broca's area, 44
- bromocriptine, 38, 45
- Brunnstrom's technique, 6–7
- BVH. *See* vestibular hypofunction
- Calcitonin, 163
- calcium channel blockers, 58, 147–9, 150
- cannabinoids, 153  
 for spasticity, 127–8
- carbamazepine, 28
- carboxymethylcellulose (CMC), 64
- cardiovascular training, for walking disorders, 112
- carotid sinus stimulation, 194
- catheterization, 207–8
- counselling, 233
- indwelling, 208
- Cawthorne-Cooksey exercises, 93
- CBD. *See* Corticobasal Degeneration
- CBT. *See* cognitive behavioural therapy
- central pattern generators (CPGs), 105–7
- cerebellum, in walking, 107
- cervical osteophylectomy, 58
- cervimeline  
 for hyposalivation, 66  
 for xerostomia, 66
- challenging behaviour, 27–8  
 boundaries in, 27  
 clinician response to, 27  
 debriefing, 28  
 personal space and, 27  
 underlying causes of, 28  
 verbal contact in, 27  
 verbal de-escalation in, 28
- chemical myotomy, 58
- chemical neurolysis, for spasticity, 128–9
- chewing gum, 64
- cholinergic drugs, for speech-language pathology, 45
- chronic aphasia, 43, 46–7
- CIMT. *See* Constraint Induced Movement Therapy
- clonazepam, 126
- clonus, 119
- clozapine, 62–3
- CMC. *See* carboxymethylcellulose
- Cochrane review, 24, 28, 64, 171  
 on aphasia, 42
- cognitive behavioural therapy (CBT), 16, 24, 146  
 defining, 24  
 focus of, 24  
 for insomnia, 17  
 manualized, 17  
 model of, 24  
 modifications, 17  
 for pain, 19  
 for PLP, 162
- cognitive functioning, 10
- coma, 30
- communication, evidence-based  
 cognitive rehabilitation for, 14–15
- complimentary interventions, for upper limb impairment, 79
- COMT inhibitors, for Parkinson's disease, 140
- conduction aphasia, 14
- Constant Therapy, 47
- Constraint Induced Language Therapy, 42–3
- Constraint Induced Movement Therapy (CIMT), 6  
 for upper limb impairment, 79
- construct validity, 4
- content validity, 4
- contingency plans, 3, 23
- conus medullaris, 203
- cortical areas, in walking, 107
- Corticobasal Degeneration (CBD), 134
- couple therapy, 233
- CPGs. *See* central pattern generators
- cranial nerves, 61
- Crede manoeuvre, 207
- crisis planning, 23
- crouch, 109
- CRS-R. *See* JFK Coma Recovery Scale – Revised
- cueing, for walking disorders, 112
- cueing hierarchies, 43
- CYP3A4-system, 37
- dantrolene, for spasticity, 127
- DBS. *See* deep brain stimulation
- decision making  
 goal planning and, 2  
 shared, 2
- decreased visual acuity, 167  
 driving and, 169–70  
 general participation and, 168–9  
 reading and, 167–8
- deep brain stimulation (DBS), 115–16  
 for DOC, 38
- default mode network (DMN), 32
- Dementia with Lewy Bodies (DLB), 134
- depression  
 in Parkinson's disease, 24, 140  
 rates of, 23–4  
 stroke and, 80–1
- detrusor overactivity (DO), 206
- detrusor-sphincter dyssynergia (DSD), 212
- dextroamphetamine, 45
- diabetic peripheral neuropathy, 108, 153–4
- Diagnostic and Statistical Manual of Mental Disorders (DSM-V), 22
- diazepam, 26
- dieticians, 5  
 in Parkinson's disease, 136, 139
- diplopia, 99, 172  
 driving and, 173  
 general participation and, 172  
 reading and, 172
- discriminant validity, 4

## Index

- disorders of consciousness (DOC), 30  
 amantadine for, 36–8  
 clinical spectrum of, 30–1  
 as continuum, 30–1  
 DBS for, 38  
 dopaminergic drugs for, 38  
 intrathecal baclofen for, 38  
 modafinil for, 38  
 neuroanatomy in, 32  
 non-pharmacological treatment, 32–6  
 pathophysiology of, 32  
 pharmacological treatment, 36–8  
 surgical treatment for, 38  
 treatment, 32  
 verticalization to near standing  
 position for, 32–4  
 zolpidem for, 37
- divided attention, 13
- dizziness, 90  
 visually induced, 94
- Dizziness Handicap Inventory, 93
- DLB. *See* Dementia with Lewy Bodies
- D-Mannose, 205
- DMN. *See* default mode network
- DOC. *See* disorders of consciousness
- donepezil, 45
- dopamine, 24–5
- dopamine agonists, for Parkinson's disease, 139
- dopaminergic drugs  
 for DOC, 38  
 for speech-language pathology, 45
- dorsal root entry zone (DREZ), 154
- driving  
 decreased visual acuity and, 169–70  
 diplopia and, 173  
 hemianopia and, 172  
 nystagmus and, 174  
 visual impairment and, 167
- DSD. *See* detrusor-sphincter dyssynergia
- DSM-V. *See* Diagnostic and Statistical Manual of Mental Disorders
- dual task training, for walking disorders, 112
- Duodopa, for Parkinson's disease, 142
- dysarthria, 43
- dysautonomic crises, 198
- dysphagia, 53, 62  
 aetiologies of, 52–3  
 aging and, 52–3  
 biofeedback for, 56–7  
 botulinum toxin for, 58  
 EMST for, 57  
 food consistency and, 54  
 general treatment of, 53–4  
 non-pharmacological treatment of, 54–8  
 pharmacological treatment of, 58  
 signs of, 53  
 surface electrical stimulation for, 57  
 surgical treatment, 58
- ED. *See* erectile dysfunction
- education, about spasticity, 120–2
- electromagnetic stimulation, 35–6  
 rationale for, 35
- electromechanical training, walking and, 113
- electrostimulation  
 for hyposalivation, 64–5  
 for xerostomia, 64–5
- Emory Ambulation Profile, 110
- emotional dysregulation, 11
- emotional functioning, psychological rehabilitation intervention for, 15–16
- emotional incontinence, 26
- EMST. *See* expiratory muscle strength training
- enriched environments, 75–6
- Epley manoeuvre, 100
- equinus, 109
- erectile dysfunction (ED)  
 local therapy for, 229  
 oral treatment for, 228–9  
 pelvic floor physiotherapy, 229–30  
 penile prosthetic surgery for, 229
- ERIGO<sup>®</sup>, 33
- EST. *See* explorative saccade training
- European Stroke Scale, 81
- EUS. *See* external urethral sphincter muscle
- evidence-based cognitive rehabilitation  
 acquisition stage, 10–11  
 adaptation stage, 10–11  
 application stage, 10–11  
 for attention, 13  
 for communication, 14–15  
 for executive functioning, 10–11  
 for hemispatial neglect, 14  
 for language, 14–15  
 for memory, 12–13  
 problem-solving strategies, 12
- executive functioning, evidence-based cognitive rehabilitation for, 10–11
- exercise-related hypotension, 193  
 fluid replacement, 193  
 non-pharmacological measures, 193
- exercises. *See also specific exercises*  
 adaptation, 93–6  
 fixation, 94–6  
 high intensity, 137  
 stroke and, 76  
 swallowing, 54–6  
 in vestibular rehabilitation, 95
- expiratory muscle strength training (EMST), for dysphagia, 57
- explorative saccade training (EST), 171
- external urethral sphincter muscle (EUS), 212
- extrapyramidal signs, in walking disorders, 114–15
- face validity, 4
- falls  
 medications associated with, 115  
 walking disorders and, 115
- Familial Dysautonomia (FD), 198  
 dysautonomic crises, 198  
 pharmacological treatment of, 198–9  
 typical, 198
- Familiar Auditory Sensory Training (FAST), 34
- family, in neurorehabilitation, 3–4
- FAST. *See* Familiar Auditory Sensory Training
- fatigue  
 psychological rehabilitation intervention for, 18  
 self-reported, 18
- FD. *See* Familial Dysautonomia
- fear, walking and, 108
- FEES. *See* fibre-optic endoscopic evaluation of swallowing
- FES. *See* functional electrical stimulation
- FGF. *See* fibroblast growth factor
- fibre-optic endoscopic evaluation of swallowing (FEES), 53
- fibroblast growth factor (FGF), 81
- fixation exercises, 94–6
- fluid intake control, 208
- fluoxetine, 80
- fluvoxamine, 45
- focused attention, 13
- food consistency, 54
- Fugl-Meyer Scale, 75, 76, 80, 81
- functional electrical stimulation (FES), 33  
 for spasticity, 124  
 for upper limb impairment, 79  
 for walking disorders, 111
- functional independence measure, 4
- functional neurosurgery, for walking disorders, 115–16
- functional walking disorders, 108
- GABA agonists, 37
- gabapentin, 80  
 for spasticity, 127
- Gabapentin, 126

- GAD-7. *See* Generalized Anxiety Disorder 7
- gait. *See* walking
- galantamine, 45
- gaze transfer, 94
- GDNF. *See* glial cell derived neurotrophic factor
- general participation
- decreased visual acuity and, 168–9
  - diplopia and, 172
  - hemianopia and, 171–2
  - nystagmus and, 173–4
  - visual impairment and, 166–7
- Generalized Anxiety Disorder 7 (GAD-7), 25
- generic VR booklet, 93
- gentamicin, 92
- Ghent Participation Scale, 4
- GIST. *See* Group Interactive Structured Treatment
- Glasgow coma scale, 4
- glaucoma, 65
- glial cell derived neurotrophic factor (GDNF), 81
- global aphasia, 14
- globus pallidus internus (GPi), 37
- glycopyrrrolate, 63
- adverse effects of, 70
  - for hypersalivation, 69–71
- goal planning
- decision making and, 2
  - impairments and, 2–3
  - negotiation in, 2
  - neurorehabilitation, 1
- GPi. *See* globus pallidus internus
- grief, 25
- Group Interactive Structured Treatment (GIST), 15
- Gufoni manoeuvre, 101
- headaches, in TBI, 18–19
- HEC. *See* hydroxyethylcellulose
- hemianopia, 170
- driving and, 172
  - general participation and, 171–2
  - reading and, 170–1
- hemispatial neglect, evidence-based cognitive rehabilitation for, 14
- high intensity exercise (HIT), 137
- hormonal replacement therapy (HRT), 230
- Hospital Anxiety and Depression Scale, 4, 25
- HPMC. *See* hydroxypropylmethylcellulose
- HRT. *See* hormonal replacement therapy
- hydration, 52
- hydroxyethylcellulose (HEC), 64
- hydroxypropylmethylcellulose (HPMC), 64
- hypersalivation
- anticholinergic medications for, 69
  - atropine for, 68–9
  - behavioural modifications for, 66
  - defining, 62
  - glycopyrrrolate for, 69–71
  - radiotherapy for, 66–7
  - scopolamine for, 69
  - surgical treatment of, 71
  - treatment for, 63
- hypersensitivity, 194
- hypertension
- pharmacological treatment of, 196
  - treatment of, 196
- hypertensive vomiting attacks, 198
- hypertonia, 119–20
- hyposalivation, 61, 64
- acupuncture for, 62–3
  - cevimeline for, 66
  - defining, 62
  - electrostimulation for, 64–5
  - pharmacological treatments for, 65
  - pilocarpine for, 65–6
  - topical preparations for, 63–4
  - treatment for, 63
- hypotension, exercise-related, 193
- IADLs. *See* instrumental activities of daily living
- ICD-10. *See* International Statistical Classification of Diseases and Related Health Problems
- ICF. *See* International Classification of Function
- Impact on Participation and Autonomy Questionnaire, 4
- impairment, 1
- of attention, 13
  - goal planning and, 2–3
  - scales, 4
- indwelling catheters, 208
- infection control, pressure ulcers, 183
- inshoe orthoses, 112
- insomnia, CBT for, 17
- instrumental activities of daily living (IADLs), upper limb impairment and, 76–9
- intercourse-outercourse approach, 232–3
- interdisciplinary team models, 5
- International Classification of Function (ICF), 1, 42
- International Statistical Classification of Diseases and Related Health Problems (ICD-10), 22, 25
- internet-based VR, 93
- interpersonal therapy (IPT), 24
- model of, 25
- Inter-Rater reliability, 4
- interventions
- adaptive, 7
  - augmenting, 6
  - neurorehabilitation, 4–5
  - priming, 5–6
  - restorative, 5
  - specific, 6–7
- intrathecal baclofen
- for DOC, 38
  - for upper limb impairment, 81
- intrathecal therapies, for spasticity, 129
- IPT. *See* interpersonal therapy
- IRT. *See* item response theory
- ischemic penumbra, 46
- item response theory (IRT), 4
- JFK Coma Recovery Scale – Revised (CRS-R), 31, 33
- kinesis, 134
- lamotrigine, 151
- language, evidence-based cognitive rehabilitation for, 14–15
- laryngectomy, 58
- larynx, 52
- laxatives, for neurogenic bowel dysfunction, 220
- levodopa, 38, 45
- for Parkinson's disease, 139–41
  - for stroke, 80
- Lidocaine, 163
- life goals, 2–3
- Life Participation Approach to Aphasia (LPAA), 42
- lip-reading, 46
- LIS. *See* locked-in syndrome
- lithium, 26
- locked-in syndrome (LIS), 31–2
- long-term neurologic conditions, salivary disorders and, 62–3
- lorazepam, 26
- lower urinary tract (LUT), 202
- augmentation cystoplasty for, 211–12
  - BoNT for, 210–11
  - conservative treatment of, 208–9
  - holistic evaluation of patient in, 203–4
  - long-term follow-up, 213–14
  - mirabegron for, 210
  - oxybutynin for, 209
  - parasympatholytic drugs for, 209
  - propiverine hydrochloride for, 209–10
  - solifenacin for, 210
  - tibial nerve stimulation for, 211
  - tolterodine for, 210
  - treatment aims, 202–3, 206
  - trospium for, 210

## Index

- lower urinary tract dysfunction, 202  
 LPAA. *See* Life Participation Approach to Aphasia  
 lubricants, for sexual dysfunction, 231  
 LUT. *See* lower urinary tract
- MAO-B inhibitors, for Parkinson's disease, 139  
 Masako manoeuvre, 56  
 Maudsley Prescribing Guidelines in Psychiatry, 28  
 MBSR. *See* mindfulness based stress reduction protocol  
 McGill pain questionnaire (MPQ), 160  
 MCS. *See* minimally conscious state  
 MDC. *See* minimum detectable change  
 MDR. *See* multi-drug resistance  
 Medical Research Council (MRC), 4  
 meditation, 18  
 Melodic Intonation Therapy, 46  
 memantine, 45  
 memory  
   evidence-based cognitive rehabilitation for, 12–13  
   external aids, 12–13  
   notebooks, 12–13  
   working, 13  
 Mendelsohn manoeuvre, 54–6  
 Ménière's disease, 92, 100  
 mental practice, for upper limb impairment, 79  
 metacognitive training, 12  
 methylprednisolone, 92  
 MI. *See* motivational interviewing  
 micturition, 209  
 mindfulness-based stress reduction protocol (MBSR), 18  
 mindfulness-based cognitive therapy, 19  
 minimally conscious state (MCS), 30, 33  
   emergence from, 30–1  
 minimum detectable change (MDC), 110  
 mirabegron, for LUT, 210  
 mirror therapy  
   for PLP, 162  
   for upper limb impairment, 79  
 MMIT. *See* Modified Melodic Intonation Therapy  
 modafinil, DOC for, 38  
 Modified Ashworth scale, 4  
 Modified Melodic Intonation Therapy (MMIT), 46  
 Modified Rankin Scale, 76  
 modified self-Epley, 91  
 moisturizing gels, 64  
 molecular drug targets (TRPV), 147–9  
   for neuropathic pain, 150–1  
 mono-synaptic stretch reflexes, 107  
 mood disorders, 22  
 mood stabilisers, 26  
 motivation, upper limb impairment treatment and, 75  
 motivational interviewing (MI), 16  
   evoking stage, 16  
   focusing stage, 16  
   initial phase, 16  
   maintenance stage, 16  
 motor skill learning, 76  
 movement, in Parkinson's disease, 137  
 MPQ. *See* McGill pain questionnaire  
 MRC. *See* Medical Research Council  
 MS. *See* multiple sclerosis  
 MSA. *See* Multiple System Atrophy  
 mucous cells, 61  
 MULT-I. *See* Music Upper Limb Therapy-Integrated  
 multidisciplinary team models, 5  
   for Parkinson's disease, 135  
 multi-drug resistance (MDR), 204  
 multi-linked musculoskeletal system, in walking, 108  
 multiple sclerosis (MS)  
   anxiety disorders and, 25  
   bipolar disorder and, 26  
   suicide and, 26–7  
 Multiple System Atrophy (MSA), 134, 186  
 music therapy  
   indication for, 34  
   rationale, 34  
   review of evidence, 34–5  
   for speech-language pathology, 46  
   for upper limb impairment, 79  
 Music Upper Limb Therapy-Integrated (MULT-I), 76
- negative thoughts, 24  
 neuroanatomy, in DOC, 32  
 neurogenic bowel dysfunction, 218  
   biofeedback for, 220  
   general treatment, 218–19  
   laxatives for, 220  
   non-pharmacological treatment of, 219–20  
   prokinetics for, 220  
   suppositories for, 220  
 neurological impairment, defining, 1  
 neuromodulation, 220–1  
 neuropathic pain  
   aetiology of, 144  
   botulinum toxin in, 154–5  
   defining, 144  
   diagnosis of, 145  
   interventional therapy for, 153–4  
   non-pharmacologic therapy for, 145–6  
   opioid analgesics for, 152–3  
   pharmacologic therapy, 146–50  
   SNRIs for, 150  
   sodium channel antagonists for, 151–2  
   tramadol for, 152–3  
   tricyclic antidepressants for, 150  
   for TRPV, 150–1  
 neuropeptides, 75–6  
 neurophysiological approaches, 6–7  
 neuropsychological assessment, 11  
 neuropsychologist, 5  
 neurorehabilitation  
   assessments in, 1  
   defining, 10  
   family in, 3–4  
   goal planning, 1  
   interventions, 4–5  
   outcome measurement, 4  
   post-acute, 15  
   team members, 5  
 Nintendo Wii Fit Plus, 98–9  
 nitrates, 58  
 NMDA receptor antagonist, 163  
 nocturnal polyuria, 210  
 non-invasive brain stimulation, 43–4  
 nonpharmacological treatment, 160–1  
 nonsteroidal anti-inflammatory drugs (NSAIDs), for PLP, 162  
 noradrenaline, 24–5  
 noradrenergic based drugs, for speech-language pathology, 45  
 norepinephrine, 45  
 Northern Manhattan Stroke study, 75  
 Norton Scale, 180, 181  
 NSAIDs. *See* nonsteroidal anti-inflammatory drugs  
 nutrition, 52  
 nystagmus, 173  
   driving and, 174  
   general participation and, 173–4  
   reading and, 173
- occupational therapist, 5, 10  
 occupational therapy, for Parkinson's disease, 135–6, 138  
 oesophageal stents, 58  
 OH. *See* orthostatic hypotension  
 older adults, vestibular impairment in, 90  
 opioid analgesics, 147–9  
   for neuropathic pain, 152–3  
   for PLP, 163  
 organizational psychology, 3  
 Orientation Books, 12–13  
 ORLA-VT, 47  
 oropharynx, 52  
 orthopaedic management, of walking disorders, 115  
 orthostatic hypotension (OH), 187–8  
   activities to avoid in, 190  
   autonomic response and, 187



- definition of, 187–8  
 non-pharmacological measures of, 190–1  
 pharmacological treatment of, 191–2  
 prevention, 191–2  
 symptoms of, 190  
 treatment of, 188–92  
 triggers of, 188  
 typical symptoms of, 188  
 orthotic devices, 7, 136  
 spasticity and, 124  
 for walking disorders, 112  
 orthotists, 5  
 oscillopsia, 99, 105–7  
 outcome measurement, neurorehabilitation, 4  
 oxybutynin, for LUT, 209  
 oxytocin, 75–6
- pain. *See also* neuropathic pain;  
 phantom limb pain  
 causes of, 18  
 CBT for, 19  
 psychological rehabilitation  
 intervention for, 18–19  
 parasympatholytic drugs, for LUT, 209  
 Parkinson's disease, 62–3, 111, 115–16, 134  
 aetiology of, 134  
 amantadine for, 140  
 anticholinergic medications for, 140  
 anxiety disorders and, 25  
 apomorphine for, 142  
 assessment, 138  
 atypical, 135  
 botulinum toxin for, 140  
 COMT inhibitors for, 140  
 depression in, 24, 140  
 dieticians in, 136, 139  
 dopamine agonists for, 139  
 Duodopa for, 142  
 incidence of, 62–3  
 levodopa for, 139–41  
 MAO-B inhibitors for, 139  
 medication for, 135  
 medication side effects in, 141  
 motor fluctuations, 140  
 motor symptoms of, 134  
 movement in, 137  
 multidisciplinary team models for, 135  
 non-motor symptoms of, 134–5  
 non-pharmacological treatment, 136  
 occupational therapy for, 135–6, 138  
 pharmacological treatment, 139–41  
 physiotherapy, 135–6, 137–8  
 speech-language therapy in, 136, 138–9  
 swallowing in, 136  
 transfers in, 138  
 Parkinson's disease nurse specialist (PDNS), 135  
 parotid gland, 61, 71  
 paroxysmal sympathetic storm/  
 hyperactivity (PSH), 196  
 medications used for, 196  
 passive movements, spasticity and, 123  
 pathophysiology, of DOC, 32  
 PDNS. *See* Parkinson's disease nurse specialist  
 PE. *See* premature ejaculation  
 pedunculopontine nucleus (PPN), 107  
 PEG. *See* percutaneous gastrostomy tube  
 PEJ. *See* percutaneous jejunostomy tube  
 pelvic floor physiotherapy, 229–30  
 pelvic muscle floor training (PFMT), 206  
 penile prosthetic surgery, 229  
 percutaneous gastrostomy tube (PEG), 58  
 percutaneous jejunostomy tube (PEJ), 58  
 peripheral lesions, 203  
 personal space, challenging behaviour and, 27  
 PFMT. *See* pelvic muscle floor training  
 PGM. *See* polyglyceryl methacrylate  
 phantom limb pain (PLP), 158, 161  
 acetaminophen for, 162  
 anticonvulsants for, 163  
 antidepressants for, 162–3  
 assessment of, 160  
 biofeedback for, 162  
 desensitizing technique, 161–2  
 factors affecting, 160  
 management, 160  
 mechanisms, 158–9  
 mirror therapy, 162  
 NSAIDs for, 162  
 opioid analgesics for, 163  
 presentation of, 159–60  
 psychogenic mechanisms, 159  
 surgical interventions, 163–4  
 phantom limb sensation (PLS), 158  
 phenol, intrathecal, 130–1  
 phobic postural vertigo, 108  
 physiotherapist, 5  
 pilocarpine  
 dosage for, 65  
 for hyposalivation, 65–6  
 for xerostomia, 65–6  
 piracetam, 45  
 PLISSIT model, 228  
 PLP. *See* phantom limb pain  
 PLS. *See* phantom limb sensation  
 pneumonia, 54
- PNF. *See* proprioceptive neuromuscular facilitation  
 polyglyceryl methacrylate (PGM), 64  
 polyneuropathy, 146  
 polyuria, nocturnal, 210  
 postprandial hypotension (PPH), 192  
 non-pharmacological measures, 192  
 pharmacological measures, 192  
 post-traumatic stress disorder (PTSD), 15–16, 26  
 postural alignment, vestibular rehabilitation and, 95–6  
 postural changes, 53  
 postural control, 90  
 postural management, of spasticity, 122  
 postural tachycardia syndrome (PoTS), 195  
 non-pharmacological measurements, 195  
 PPH. *See* postprandial hypotension  
 PPN. *See* pedunculopontine nucleus  
 Practice Guidelines, 12  
 Practice Standards, 10, 12, 19  
 pramipexole, 139  
 pregabalin, 80  
 for spasticity, 127  
 Pregabalin, 126  
 premature ejaculation (PE), 232  
 pressure ulcers, 178  
 aetiology, 178  
 category I, 180  
 category II, 180  
 category III, 180  
 category IV, 180  
 causes of, 178–9  
 classification of, 179  
 complications of, 181  
 healing, 180–1  
 infection control, 183  
 management of, 181–3  
 pressure relief, 181  
 prevention, 179  
 risk assessments, 180  
 risk factors, 179  
 support surfaces, 181–2  
 surgical intervention for, 183  
 wound debridement for, 183  
 wound dressings for, 183  
 wound healing for, 183  
 preventive rehabilitation, 5, 7  
 PRF. *See* pulsed radiofrequency  
 priming interventions, 5–6  
 ProACT, 213  
 progressive resisted exercise, 111  
 Progressive Supranuclear palsy (PSP), 134  
 prokinetics, for neurogenic bowel dysfunction, 220

## Index

- propiverine hydrochloride, for LUT, 209–10  
 proprioceptive neuromuscular facilitation (PNF), 6–7  
 proton pump inhibitors, 58  
 PSH. *See* paroxysmal sympathetic storm/hyperactivity  
 PSP. *See* Progressive Supranuclear palsy  
 psychiatrists, 136  
 psychoeducation, 17–18  
 psychological rehabilitation  
   intervention, 15  
   for emotional functioning, 15–16  
   for fatigue, 17–18  
   for pain, 18–19  
   for sleep, 16–18  
 psychologists, 136  
 psychometrics, 4  
 psychotherapy, 19  
 PTSD. *See* post-traumatic stress disorder  
 pulsed radiofrequency (PRF), 153  
 punch biopsy, 145  
 pusher syndrome, 107–8  
  
 radiotherapy  
   adverse effects of, 66–7  
   for hypersalivation, 66–7  
 rasagiline, 139  
 RASCH analysis, 4  
 reading  
   decreased visual acuity and, 167–8  
   diplopia and, 172  
   hemianopia and, 170–1  
   lip-reading, 46  
   nystagmus and, 173  
   visual impairment and, 166  
 recovery, promotion of, 6  
 recurvatum, 109  
 rehabilitation nurse, 5  
 rehabilitation physician, 5  
 relaxation, applied, 25–6  
 reliability  
   Inter-Rater, 4  
   Test-Retest, 4  
 reperfusion therapies, for upper limb impairment, 80–1  
 repetitive task training, for upper limb impairment, 79  
 repetitive transcranial magnetic stimulation (rTMS), 5–6  
   for aphasia, 43–4  
 responsiveness, 4  
 restorative interventions, 5  
 Rivermead Motor Assessment, 80  
 robotics  
   for upper limb impairment, 79  
   walking and, 113  
   role transitions, 25  
  
 Rood's approach, 6–7  
 ropinirole, 139  
 rTMS. *See* repetitive transcranial magnetic stimulation  
  
 saccades, 95–5  
 saccadic substitution, 93–4  
 sacral neuromodulation (SNM), 211  
 SafeStraw, 54  
 saliva. *See also* hypersalivation; hyposalivation  
   control of, 61  
   flow rate, 61, 62  
   production, 61  
   stimulated, 61, 62  
   unstimulated, 61, 62  
 salivary disorders, long-term  
   neurologic conditions and, 62–3  
 scopolamine, 63  
   formulations of, 69  
   for hypersalivation, 69  
 SCS. *See* spinal cord stimulators  
 seating, spasticity and, 123–4  
 selective attention, 13  
 selective dorsal rhizotomy, 131  
 selective serotonin reuptake inhibitor (SSRI), 24–5, 45, 80, 147–9  
   for anxiety disorders, 26  
 Selegiline, 139  
 self-efficacy, 3  
 self-feeding, 7  
 self-monitoring, 12  
 Semont manoeuvre, 100  
 sensate focus, 232  
 sensorimotor rhythm (SMR), 81  
 sensory interventions, for upper limb impairment, 79  
 sensory rehabilitation, walking and, 114  
 sensory re-weighting, 94  
   vestibular rehabilitation and, 96–8  
 sensory stimulation  
   indication for, 34  
   rationale, 34  
   review of evidence, 34–5  
 sensory-motor feedback loops, in swallowing, 54  
 Sentactics, 47  
 Sentence-Shaper, 47  
 serotonin, 24–5, 45  
 serotonin syndrome, 152–3  
 serotonin-noradrenaline reuptake inhibitors (SNRI), 24–5  
   for neuropathic pain, 150  
 serous cells, 61  
 sex therapy, 232  
 sexual activity planning, 230–1  
 sexual dysfunction, 224  
   clinical overview, 224–7  
   high level, 228, 231  
   level 2, 228  
   low level, 225, 228  
   lubricants for, 231  
   medications for, 231  
   middle level, 225  
   psychological therapy for, 231–3  
   rehabilitation principles, 233–4  
   sensorimotor levels of, 226–7  
   treatments, 226–7, 228, 231  
 Shaker Exercise, 56  
 shared decision making, 2  
 shoes  
   inshoe orthoses, 112  
   for walking disorders, 112  
 sialorrhea. *See* hypersalivation  
 sildenafil, 231  
 Sinemet, 80  
 Sjogren's syndrome, 65–6  
 skilled nursing facilities (SNF), 74–5  
 sleep  
   diary, 17–18  
   hygiene, 17  
   psychological rehabilitation  
     intervention for, 16–18  
   rules, 17–18  
   TBI and, 16–17  
 SLP. *See* speech-language pathologists  
 SMART goals, 3  
 smart tablets, 47  
 SMR. *See* sensorimotor rhythm  
 SNF. *See* skilled nursing facilities  
 SNM. *See* sacral neuromodulation  
 SNRI. *See* serotonin-noradrenaline reuptake inhibitors  
 social workers, 5  
 sodium channel antagonists, 147–9  
   for neuropathic pain, 151–2  
 sodium valproate, 26, 28  
 solifenacin, for LUT, 210  
 somato-autonomic reflex arc surgery, 221  
 SP. *See* stump pain  
 spasms, 119  
   triggers, 120  
 spasticity, 119  
   active exercise for, 122–3  
   assessment, 120  
   baclofen for, 125  
   benzodiazepines for, 127  
   botulinum toxin for, 128–9  
   cannabinoids for, 127–8  
   chemical neurolysis for, 128–9  
   dantrolene for, 127  
   education about, 120–2  
   FES for, 124  
   focal treatment of, 128  
   gabapentin for, 127  
   goal setting, 120  
   individualized treatment plan, 120  
   intra-thecal therapies for, 129

- management algorithm, 121  
 oral medication for, 125–8  
 orthotic devices and, 124  
 passive movements and, 123  
 pathophysiology of, 119–20  
 postural management of, 122  
 pregabalin for, 127  
 seating and, 123–4  
 self-management, 120–2  
 splinting and, 124  
 standing and, 123  
 stretching for, 123–4  
 stroke and, 80  
 tizanidine for, 125–7  
 treatment modalities, 124–5  
 triggers, 120  
   in walking disorders, 114  
 specific interventions, 6–7  
 speech therapist, 5  
 speech-language pathologists (SLP), 10  
 speech-language pathology, 41, 47  
   behavioural treatment for, 41–3  
   cholinergic drugs for, 45  
   computer technology for, 46–7  
   dopaminergic drugs for, 45  
   glutamatergic drugs for, 45  
   medical and surgical treatment of, 46  
   music therapy for, 46  
   noradrenergic based drugs for, 45  
   in Parkinson's disease, 136, 138–9  
   pharmacological treatment, 44–5  
 Spinal Cord Independence measure, 4  
 spinal cord stimulators (SCS), 153–4  
 splinting  
   spasticity and, 124  
   for walking disorders, 111–12  
 SSRI. *See* selective serotonin reuptake inhibitor  
 standing, spasticity and, 123  
 stem cell therapy, for upper limb impairment, 81–2  
 stiff knee, 109  
 stimulated saliva, 61, 62  
 STN. *See* subthalamic nucleus  
 stoma formation surgery, 221  
 straws, 54  
 strength training, for upper limb impairment, 79  
 stress, 22  
 stressors, identification of, 23  
 stretching  
   for spasticity, 123–4  
   for upper limb impairment, 79  
   for walking disorders, 111–12  
 stroke  
   animal studies on, 75–6  
   anxiety disorders and, 25  
   disorders in, 47  
   exercise and, 76  
   spasticity and, 80  
   treatment, 74–5  
   upper limb impairment and, 74  
 stump pain (SP), 158  
 subcortical systems, in walking, 107  
 sublingual gland, 61  
 submandibular gland, 61  
   transposition of, 71  
 substance abuse, 15–16  
 subthalamic nucleus (STN), 115–16  
 suicide, 26–7  
   deaths from, 26  
   MS and, 26–7  
   risk assessment, 27  
 supine hypertension, 195  
   non-pharmacological measurements, 195  
   pharmacological measurements, 196  
 suppositories, for neurogenic bowel dysfunction, 220  
 surface electrical stimulation, for dysphagia, 57  
 surgical external sphincterotomy, 212  
 sustained attention, 13  
 swallowing. *See also* dysphagia  
   evaluation of, 53  
   exercises, 54–6  
   oesophageal phase, 52  
   oral preparatory phase of, 52  
   oral propulsive phase of, 52  
   in Parkinson's disease, 136  
   pharyngeal phase, 52  
   sensory-motor feedback loops in, 54  
   structures in, 52  
 syncope, 193–4  
   non-pharmacological measurements, 194–5  
   pathophysiology of, 194  
   situational, 194  
   treatment of, 194  
 systemic desensitization, 232  
 tachycardia, 199  
 Tai Chi, 113, 145–6  
 task specific practice, 7  
 TASR. *See* tool for assessment of suicide risk  
 TBI. *See* traumatic brain injury  
 tDCS. *See* transcranial direct current stimulation  
 team models  
   interdisciplinary, 5  
   multidisciplinary, 5, 135  
   neurorehabilitation, 5  
   transdisciplinary, 5  
 TENS. *See* transcutaneous electrical stimulation  
 Test-Retest reliability, 4  
 therapy tasks, 42  
 thermal stimulation, 54  
 thyroid notch, 54–6  
 thyroid stimulating hormone (TSH), 145  
 tibial nerve stimulation, for LUT, 211  
 Time Pressure Management (TPM), 13  
 tizanidine, 126  
   for spasticity, 125–7  
 TMS. *See* transcranial magnetic stimulation  
 toileting, behavioural therapy and, 207  
 tolterodine, for LUT, 210  
 tool for assessment of suicide risk (TASR), 27  
 Touchspeak, 47  
 TPM. *See* Time Pressure Management  
 traditional exercise programs, 7  
 tramadol, for neuropathic pain, 152–3  
 transanal irrigation, 220  
 transcranial direct current stimulation (tDCS), 5–6, 41, 43  
   anodal, 35  
   for aphasia, 44  
   cathodal, 35, 44  
   effects of, 44  
   inhibitory, 44  
   technique, 35  
   for upper limb impairment, 79  
 transcranial magnetic stimulation (TMS), 35, 43  
   application of, 43–4  
   repetitive, 5–6, 43–4  
   for upper limb impairment, 79  
 transcutaneous electrical stimulation (TENS), 146  
 transdisciplinary team models, 5  
 transient hypertensive surges, 198  
 traumatic brain injury (TBI), 11–12, 14, 18, 90  
   diagnoses after, 15–16  
   headaches in, 18–19  
   sleep and, 16–17  
 treadmill training, 6, 113  
 tricyclic antidepressants, 24–5, 62–3, 147–9  
   for neuropathic pain, 150  
 triggered voiding, 206–7  
 trospium, for LUT, 210  
 TRPV. *See* molecular drug targets  
 TSH. *See* thyroid stimulating hormone  
 unimanual training, 76–9  
 unresponsive wakefulness syndrome (UWS), 30, 33  
   visual pursuit and, 31  
 unstimulated saliva, 61, 62  
 upper limb impairment, 74  
   associated disorders, 74  
   bilateral arm training for, 79  
   biofeedback for, 79  
   Bobath approach for, 79  
   brain-machine interfaces for, 81–2



## Index

- upper limb impairment (cont.)  
 CIMT for, 79  
 complimentary interventions for, 79  
 FES for, 79  
 IADLs and, 76–9  
 intrathecal baclofen for, 81  
 mental practice for, 79  
 meta-analyses, 76  
 mirror therapy for, 79  
 motivation in treatment of, 75  
 music therapy for, 79  
 non-pharmacological treatments, 76–9  
 pharmacological treatment for, 80–1  
 reperfusion therapies for, 80–1  
 repetitive task training for, 79  
 robotics for, 79  
 sensory interventions for, 79  
 stem cell therapy for, 81–2  
 strength training for, 79  
 stretching for, 79  
 stroke and, 74  
 surgical treatment for, 81–2  
 tDCS for, 79  
 TMS for, 79  
 treatment timing and setting, 74–6  
 Upper Motor Neuron syndrome, 111  
 urinary diversion, 212  
 urinary tract infection (UTI), 204  
   investigations, 205–6  
   treatment, 204–5  
 urologists, 136  
 UTI. *See* urinary tract infection  
 UWS. *See* unresponsive wakefulness syndrome
- validity  
   construct, 4  
   content, 4  
   discriminant, 4  
   face, 4  
 VAS. *See* visual analogue scale  
 vascular endothelial growth factor (VEGF), 81  
 verbal contact, in challenging behaviour, 27  
 verbal de-escalation, in challenging behaviour, 28  
 verticalization to near standing position  
   contraindications for, 32–3  
   description of, 33  
   for DOC, 32–4  
   indication for, 32–3  
   rationale for, 32–3  
   review of evidence, 33–4  
 vertigo, 90, 105–7  
   phobic postural, 108
- vestibular compensation, 100  
 vestibular hypofunction (BVH), 99–100  
 vestibular impairment, 90  
   incidence of, 90  
   in older adults, 90  
   pharmacotherapy, 91–2  
   surgery for, 91–2  
   treatment types, 91–2  
 vestibular migraine, 99  
 vestibular rehabilitation, 91, 100  
   adaptation exercises in, 94–6  
   customized, 94–100  
   dual-task activities and, 98  
   efficacy of, 99–100  
   exercises in, 95  
   factors affecting outcome of, 99  
   neurophysiological basis for, 93–4  
   postural alignment and, 95–6  
   sensory re-weighting and, 96–8  
   virtual reality-based techniques, 98–9  
 vestibulo-ocular reflex (VOR), 93–4, 114  
 VFSS. *See* videofluoroscopic swallowing study  
 vibrostimulation, 230  
 videofluoroscopic swallowing study (VFSS), 53  
 virtual reality, walking disorders and, 113  
 virtual reality-based techniques, vestibular rehabilitation, 98–9  
 visual analogue scale (VAS), 160  
 visual impairment. *See also* decreased visual acuity  
   driving and, 167  
   general participation and, 166–7  
   reading and, 166  
 visual pursuit, UWS and, 31  
 visual scanning training, 14  
 VOR. *See* vestibulo-ocular reflex
- walking  
   aids, 113  
   analysis, 109–10  
   anxiety disorders and, 108  
   assessment, 110  
   balance and, 113  
   cerebellum in, 107  
   cortical areas in, 107  
   electromechanical training and, 113  
   fear and, 108  
   freezing, 137  
   gait cycle, 106  
   gait instability, 90  
   multi-linked musculoskeletal system in, 108  
   outcome measures, 110  
   phases of, 105  
   robotics and, 113  
   sensory rehabilitation and, 114  
   sensory systems in, 105–7  
   subcortical systems in, 107  
   task-related training, 113  
 walking disorders  
   cueing for, 112  
   dual task training for, 112  
   extrapyramidal signs in, 114–15  
   falls and, 115  
   FES for, 111  
   functional, 108  
   functional neurosurgery for, 115–16  
   high level, 107–8  
   management, 110  
   non-pharmacological treatment, 111  
   objective assessment of, 109–10  
   orthopaedic management of, 115  
   orthotic devices for, 112  
   pharmacological treatment of, 114  
   shoes for, 112  
   spasticity in, 114  
   splinting for, 111–12  
   stretching for, 111–12  
   subjective assessment of, 109  
   virtual reality and, 113  
 Waterlow scale, 182  
 Western Aphasia Battery, 44  
 WHO. *See* World Health Organization  
 Wilson's disease, 62–3  
 working memory, 13  
 World Health Organisation (WHO), 1, 42  
   handicap scale, 4  
 wound debridement, for pressure ulcers, 183  
 wound dressings, for pressure ulcers, 183  
 wound healing, for pressure ulcers, 183
- xerogenic medications, 62–3  
 xerostomia. *See* hyposalivation
- yoga, 18
- zolpidem  
   for DOC, 37  
   evidence for, 37  
   indication for, 37  
   pharmacology of, 37  
   rationale, 37  
   side effects of, 37